Summary: “If MAPS is ‘MDMA 1.0,’ I would say that what ATAI [and EmpathBio] is working on is ‘MDMA 0.5,”‘ says MAPS Founder Rick Doblin, Ph.D., in regards to ATAI’s EmpathBio psychedelic drug company developing MDMA derivatives to treat PTSD. Doblin points out that there is less available research on the MDMA derivative from EmpathBio and the focus on scaling the treatment by shortening the therapy aspect, a part of MAPS’ treatment protocol that Doblin finds essential to treating PTSD with MDMA-assisted psychotherapy.
Originally appearing here.
